Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Free Report) saw a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 934,300 shares, a drop of 23.4% from the January 31st total of 1,220,000 shares. Based on an average daily volume of 690,700 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.3% of the shares of the company are sold short.
Institutional Trading of Tiziana Life Sciences
A number of institutional investors have recently added to or reduced their stakes in TLSA. Sanctuary Advisors LLC acquired a new position in Tiziana Life Sciences during the third quarter worth $864,000. Bison Wealth LLC acquired a new position in shares of Tiziana Life Sciences during the 4th quarter worth $30,000. Geode Capital Management LLC boosted its position in shares of Tiziana Life Sciences by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock worth $171,000 after buying an additional 27,041 shares in the last quarter. Finally, Zhang Financial LLC grew its stake in Tiziana Life Sciences by 34.3% in the 4th quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock valued at $65,000 after acquiring an additional 23,800 shares during the last quarter.
Tiziana Life Sciences Stock Performance
TLSA stock opened at $1.13 on Tuesday. Tiziana Life Sciences has a one year low of $0.41 and a one year high of $1.74. The company has a fifty day moving average of $0.78 and a 200-day moving average of $0.90.
About Tiziana Life Sciences
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Read More
- Five stocks we like better than Tiziana Life Sciences
- The 3 Best Retail Stocks to Shop for in August
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- What to Know About Investing in Penny Stocks
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
